Level Four Advisory Services’s Aurinia Pharmaceuticals AUPH Stock Holding History

Level Four Advisory Services’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-236,800	Closed	-$2.13M	–	754
2024 Q1	$2.13M	Hold	236,800	–	–	0.12%	192
2023 Q4	$2.13M	Sell	236,800 -15,300	-6%	-$126K	0.12%	188
2023 Q3	$1.96M	Buy	252,100 +2,700	+1%	+$26.4K	0.13%	190
2023 Q2	$2.41M	Sell	249,400 -800	-0.3%	-$8.3K	0.15%	158
2023 Q1	$2.74M	Buy	250,200 +239,000	+2,134%	+$2.11M	0.18%	137
2022 Q4	$48.4K	Hold	11,200	–	–	﹤0.01%	655
2022 Q3	$84K	Buy	11,200 +1,000	+10%	+$8.66K	0.01%	525
2022 Q2	$103K	Buy	+10,200	New	+$114K	0.01%	535
2022 Q1	–	Sell	-10,650	Closed	-$244K	–	651
2021 Q4	$244K	Buy	+10,650	New	+$252K	0.02%	559

Other funds holding AUPH

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Level Four Advisory Services's AUPH Position: Q2 2024 in Review

Level Four Advisory Services sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2024, closing a stake of 236,800 shares — an estimated $2.13M sold.

Level Four Advisory Services first reported a position in AUPH in Q4 2021 and held it in 9 quarters. The position peaked at $2.74M in Q1 2023. 171 funds tracked by Wall St. Rank hold AUPH as of Q2 2024.

Level Four Advisory Services reported no remaining Aurinia Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Level Four Advisory Services sold 236,800 Aurinia Pharmaceuticals shares in Q2 2024, an estimated $2.13M.
Level Four Advisory Services first reported a position in Aurinia Pharmaceuticals in Q4 2021 and held it in 9 quarters.
Level Four Advisory Services's Aurinia Pharmaceuticals position peaked at $2.74M in Q1 2023.
171 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2024.

Based on Level Four Advisory Services's 13F filing for Q2 2024, filed 9 Aug 2024.